Related Experiment Video
Updated: Jun 29, 2025
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
[Gastrointestinal stromal tumors : Where do we stand?]
Eva Wardelmann1, Anna Kuntze2, Artem Voloshin2
1Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland. eva.wardelmann@ukmuenster.de.
Abstract:
For more than 20 years gastrointestinal stromal tumors (GIST) have been a paradigm for a targeted treatment with tyrosine kinase inhibitors. A fundamental prerequisite for a neoadjuvant or adjuvant treatment of localized GIST or an additive treatment of metastatic GIST is the molecular typing of tumors, ideally at the initial diagnosis. In addition, the possibility of a hereditary or syndromic predisposition must be considered because this results in consequences for the treatment and a different follow-up strategy.
Insights
Molecular typing of gastrointestinal stromal tumors (GIST) is crucial for targeted therapy with tyrosine kinase inhibitors. Considering hereditary predispositions impacts treatment and follow-up strategies for GIST patients.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Gastrointestinal stromal tumors (GIST) have been a model for targeted therapy using tyrosine kinase inhibitors for over two decades.
- Accurate molecular subtyping of GIST is essential for effective treatment strategies.
Purpose of the Study:
- To emphasize the importance of molecular subtyping in GIST diagnosis and treatment.
- To highlight the clinical implications of identifying hereditary or syndromic predispositions in GIST patients.
Main Methods:
- Review of current therapeutic approaches for GIST.
- Analysis of diagnostic criteria for GIST molecular subtyping.
- Evaluation of the impact of hereditary factors on GIST management.
Main Results:
- Molecular typing of GIST is a prerequisite for neoadjuvant, adjuvant, or metastatic treatment selection.
- Identification of specific mutations guides the choice of tyrosine kinase inhibitors.
- Hereditary or syndromic predispositions necessitate tailored treatment and follow-up plans.
Conclusions:
- Comprehensive molecular profiling at initial diagnosis is critical for optimal GIST management.
- Considering hereditary factors ensures personalized care and improved outcomes for GIST patients.
- Targeted therapies, guided by molecular diagnostics, have revolutionized GIST treatment.
